This product theater will provide information on tardive dyskinesia (TD) in long-term care (LTC) facilities and review the efficacy and safety data from the pivotal and the long-term open-label extension studies for AUSTEDO. Participants will learn how the impact of TD affects both residents and staff at LTC facilities, how routinely observing and monitoring residents for abnormal movements can inform treatment decisions, and how to distinguish TD from drug-induced parkinsonism in LTC residents. Also, the appropriate dosing and titration of AUSTEDO XR will be discussed. At the end of the session, participants will be invited to take part in a Q&A session.